USAPharmaceutical giant Eli Lilly announces partnership with OpenAI The two companies have reached a cooperation agreement to use the latter's generative AI technology to develop newAntimicrobial drugs, used forTreating drug-resistant pathogens.
Eli Lilly said that currentlyAntimicrobial resistance (AMR）AMR is one of the greatest threats to global public health and development.All regions, all income levelsof countries, with poverty and inequality exacerbating the problem, with the greatest impacts and risks particularly in low- and middle-income countries.Misuse and overuse of antibioticsIt is a major driver of the development of drug-resistant pathogens, exacerbating the threat to global health.
The World Health Organization (WHO) released a report this month stating that AMR has becomeTop 10 global public health threatsWhen bacteria, viruses, fungi and parasites areNo more reactionAMR occurs when the number of infections increases, making people sicker and increasing the risk of hard-to-treat infections, disease and death. WHO has called for an urgent need for new innovative medicines to treat serious infections and replace those that have become ineffective due to widespread use.
Brad Lightcap, COO of OpenAI, said that advanced AI technology is expected to bring "innovative breakthroughs" to the pharmaceutical industry. Diogo Lau, Chief Information and Digital Officer of Eli Lilly, said that generative AI isAccelerating the discovery of new antimicrobial agentsandDevelop customized, specialized technologiesOpening up new opportunities to combat drug-resistant pathogens.